$9.50
0.00%
Nasdaq, Fri, Aug 22 2025
ISIN
US73730P1084
Symbol
PSTX

Poseida Therapeutics Inc Stock price

$9.50
+0.00 0.00% 1M
+0.00 0.00% 6M
-0.10 1.04% YTD
+6.70 239.29% 1Y
+5.85 160.27% 3Y
+0.95 11.11% 5Y
-5.85 38.11% 10Y
-5.85 38.11% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.00 0.00%
ISIN
US73730P1084
Symbol
PSTX
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$230.9m
Shares outstanding
97.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
37.9%
Return on Equity
-119.0%
ROCE
-29.0%
ROIC
-393.1%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$150.9m | $150.1m
EBITDA
$-57.0m | $-125.3m
EBIT
$-62.5m | $-95.3m
Net Income
$-60.8m | $-94.4m
Free Cash Flow
$-17.1m
Growth (TTM | estimate)
Revenue
202.9% | 131.9%
EBITDA
56.6% | -1.1%
EBIT
54.3% | 26.4%
Net Income
53.8% | 23.5%
Free Cash Flow
73.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-37.8% | -83.5%
EBIT
-41.4%
Net
-40.3% | -62.9%
Free Cash Flow
-11.4%
More
EPS
$-0.6
FCF per Share
$-0.2
Short interest
5.1%
Employees
350
Rev per Employee
$180.0k
Show more

Is Poseida Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Poseida Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Poseida Therapeutics Inc forecast:

7x Hold
70%
3x Sell
30%

Analyst Opinions

10 Analysts have issued a Poseida Therapeutics Inc forecast:

Hold
70%
Sell
30%

Financial data from Poseida Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
151 151
203% 203%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
8% 8%
27%
- Research and Development Expense 172 172
16% 16%
114%
-57 -57
57% 57%
-38%
- Depreciation and Amortization 5.48 5.48
1% 1%
4%
EBIT (Operating Income) EBIT -63 -63
54% 54%
-41%
Net Profit -61 -61
54% 54%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Poseida Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Poseida Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio (“Imagene”), of the combined company after the anticipated closing.

Company Profile

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.

Head office United States
CEO Kristin Yarema
Employees 350
Founded 2014
Website poseida.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today